Manufacturers

Work worth doing: Innovative field solutions

Manufacturers

Essential skills for outsourced field solutions teams

Copay accumulator adjustment programs significantly increase patient financial burden

Manufacturers

Yes, you can commercialize on your own—even if you're an emerging biopharma

Manufacturers

The essential guide to drug commercialization

Manufacturers

Branding: The difference between good and great patient assistance programs

Manufacturers

Innovative agreements: Exploring alternative payment models

Research poster: The current impact of ICER assessments on payer decision making

Skyrocketing growth in PBM formulary exclusions continues to raise concerns about patient access

Medicaid Best Price and Its Implications on Cell and Gene Therapy Products

Manufacturers

Six insights driving the evolution of FormularyDecisions®

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

Joint clinical assessment in the EU: Pan-European HTA for drugs and medical devices will become reality 

Accelerated approval not accelerated access: Clinical trials required for coverage of Alzheimer's treatments

The impact of the Build Back Better Act (BBBA) on rare disease innovation

Is NICE becoming nicer?

Evidence generation and approval of digital health applications in Germany

340B – A missed opportunity to address those that are medically underserved

ASCVD needs innovation

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Health disparities and health technology assessment: Current value assessment frameworks fall short

Elucidating ICER’s methodologies for Unsupported Price Increase assessments  

Equity considerations in US value assessment: Opportunities ahead

Copay accumulators and the impact on patients

Manufacturers

Buy-and-bill vs. self-administered: Field services remove barriers across access points

Manufacturers

Launching field services in the midst of COVID-19

The impact of obesity on COVID-19 outcomes of hospitalizations and mortality

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Manufacturers

Evaluating the modern field reimbursement and access program: key considerations

Manufacturers

Pharma in the field: Heather's story

New Copay Accumulator Policy Could Ignite Payer Trend on Medical Benefit Products

Manufacturers

Pharma in the field: Ashley's story

Manufacturers

Pharma in the field: Tierra's story

HTA Quarterly | Winter 2020

Manufacturers

PAP 2020 panel recap: Navigating COVID-19

COVID-19 Drives Through the American Heartland

Webinar: 5 Years of ICER - Insights and Impact on Payers

Skyrocketing Growth in PBM Formulary Exclusions Raises Concerns About Patient Access

Case study: Gaining payer attention through digital innovation

Manufacturers

Rethink field services: Three myths keeping access barriers in front of your product

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Medicaid's Proposed “Line Extension” Redefinition Imperils Innovation and Patient Access

Manufacturers

Pharma in the field: Sales reps vs. reimbursement and access specialists

Patient Support in the Time of COVID-19: Five Ways to Adapt

Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1

Manufacturers

Webinar: Patient Assistance in the Wake of COVID19

Manufacturers

How COVID-19 Will Impact Patient Support

Impact of COVID-19 Pandemic on Patient Access Programs

Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies

Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity

Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine